mRNA Reagents
for
Walter Reed Army Institute of Research (WRAIR)

General Information:

This is an RFI as defined in FAR 15.201(e) to ascertain whether a commercial item exists that provides the capabilities described herein.

This RFI is issued solely for information and planning purposes and does not constitute a solicitation. All information received in response to this RFI will be treated as business confidential information. Nonetheless, submitters should properly mark their responses if the information is confidential. Responses to the RFI will not be returned. Responses to this notice are not offers and cannot be accepted by the Government to form a binding contract. Responders are solely responsible for all expense associated with responding to this RFI.

RFI Response and due date: 17 December 2018

Instructions to Responders:

Responses from all capable and qualified sources are encouraged to respond to this request.

White papers should adhere to the following formatting and outline instructions:

1. All submissions shall be made electronically and be in one of the following formats: Microsoft Word or Adobe PDF.

2. Cover Page (1page)
• Title
• Organization
• Responders technical and administrative points of contact (names, addresses, phone, fax number and email addresses)
• Topic area(s) addressed

3. Completed Attachment 1 and Attachment 2. Please note that the response shall provide sufficient technical data to determine how you fully meet the requirements as specified in Attachment 2.

Please note that responses are due no later than 17 December 2018, 3:00pm, Eastern. The preferred method of submission is via email. The point of contact for this action is Dawn Jennings, Contract Specialist, [email protected]. Only electronic responses are requested. No evaluation letters and/or results will be issued to the respondents. At this time no solicitation exists; therefore, please do not request a copy of the solicitation. NO PHONE CALLS PLEASE. It is the responsibility of any potential offeror to monitor this site for the release of any solicitation or synopsis.

Background/Overview: WRAIR is seeking sources that can provide the synthesis and delivery of mRNA products in different quantities and different sequences as needed by Malaria Vaccine Branch (MVB). MVB will provide a mRNA sequence to the contractor who will synthesize that sequence as well as adding stabilizing factors to both ends of the mRNA (at the 5' and 3' ends).

Specific requirements are provided within Attachment 2.